Healthcare & Pharma top picks: AI and personalization fuel new era of health innovation
Older updates:
EDGE Insights
Notarize: The online remote notarization service
EDGE Insights
Ramp: The corporate card and expense management company
EDGE Insights
Betterment: The investment app with automated investing, financial planning, and cash accounts
EDGE Insights
NVIDIA Q3 FY2025 recap
EDGE Insights
RegTech
EDGE Insights
Ripple: The blockchain-based digital payment company
EDGE Insights
H2O.ai: The open-source AutoML platform
EDGE Insights
PsiQuantum: A pioneer in advancing quantum computing hardware development
EDGE Insights
State of tech in Financial Services: How AI, blockchain, and biometrics are forging the future
EDGE Insights
Valimail: The email authentication and security solutions provider
By Abdul Azeez, Jehan Saldin · May 20, 2024
Healthcare & Pharma top picks: AI and personalization fuel new era of health innovation
In the past two editions, the framework has identified the most promising startups in emerging industries, equipping innovators with the knowledge to identify the best companies before they reach product maturity.
Drugs discovered by AI are nearing commercialization, as candidates advance through the clinical pipeline. Most notably, Insilico Medicine successfully moved its lead drug candidate into Phase II clinical trials, making it the first AI-discovered drug to reach this stage of human clinical trials. Meanwhile, Exscientia also advanced two of its four drug candidates into Phase I/II clinical trials.
Healthcare & Pharma startups are increasingly focused on offering tailored therapeutics using novel methods such as nanopore sequencing (Oxford Nanopore) and analyzing data from wearable devices (Movano Health) and patient healthcare records (Atropos Health) to gather individual-level insights into patients. This approach enables them to develop personalized health plans and therapeutics to better treat patients.
Gene treatments hold immense potential in the healthcare space, with companies such as CRISPR Therapeutics pioneering human gene editing techniques and showing promise for treating genetic disorders by accurately altering problematic genes. Meanwhile, Autolus is leading the charge in cell and gene therapy, leveraging advanced cell programming technologies to develop cutting-edge treatments that harness the body's immune system to combat diseases like cancer.
SPEEDA Edge top picks for 2024
Source: SPEEDA Edge
Contact us
Gain access to all industry hubs, market maps, research tools, and more
Get a demo
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.